Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C21H22N2O3 |
| Molecular Weight | 350.411 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+]12CC[C@@]34[C@@H]1C[C@@H]5[C@@H]6[C@@H]3N(C7=CC=CC=C47)C(=O)C[C@@H]6OCC=C5C2
InChI
InChIKey=ADTDBAKUQAKBGZ-VXJIXCKJSA-N
InChI=1S/C21H22N2O3/c24-18-10-16-19-13-9-17-21(6-7-23(17,25)11-12(13)5-8-26-16)14-3-1-2-4-15(14)22(18)20(19)21/h1-5,13,16-17,19-20H,6-11H2/t13-,16-,17-,19-,20-,21+,23?/m0/s1
| Molecular Formula | C21H22N2O3 |
| Molecular Weight | 350.411 |
| Charge | 0 |
| Count |
|
| Stereochemistry | EPIMERIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Strychnine-N-oxide is the major metabolite of Strychnine. Strychnine, the major alkaloid present in $trychnos:nuxypmicagseeds has been reported to stimulate
the entire central nervous system with preference for the
spinal cord. It is a powerful convulsant and because of
this property, it is an important pharmacological tool as
it plays a unique role as an inhibitor of post synaptic
inhibitory impulses. It is useful to study inhibitory
transmitter and receptor types. However, because of its
extreme toxicity, strychnine does not have any therapeutic
application in the Western system of medicine. Strychnine-N-oxide is less toxic and less convulsive than strychnine itself. However, strychnine N-oxide is not
being used as a therapeutic agent now probably because of the threat of convulsions at higher doses. Strychnine-N-oxide is a muscarinic allosteric agent.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
|||
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
|||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
|||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Concise Syntheses of bis-Strychnos Alkaloids (-)-Sungucine, (-)-Isosungucine, and (-)-Strychnogucine B from (-)-Strychnine. | 2016-08-08 |
|
| Determination of strychnine, brucine, strychnine N-oxide, and brucine N-oxide in plasma samples after the oral administration of processed semen strychni extract by high-performance liquid chromatography with ultrasound-assisted mixed cloud point extraction. | 2016-07 |
|
| Metabolism of strychnine in vitro. | 1985-11-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.drugfuture.com/toxic/q127-q978.html
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE: Subcutaneous
SPECIES OBSERVED: Rodent - mouse
DOSE/DURATION: 24500 ug/kg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9986715
Binding affinity at the NMS liganded human muscarinic acetylcholine receptor M1 was estimated as log affinity (log1/M) = 3.8.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:55:38 GMT 2025
by
admin
on
Mon Mar 31 20:55:38 GMT 2025
|
| Record UNII |
774C760V46
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
774C760V46
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | |||
|
230-656-5
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | |||
|
127569
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | |||
|
24951
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | |||
|
73393
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | |||
|
m10256
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | Merck Index | ||
|
7248-28-4
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | |||
|
132703
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY | |||
|
DTXSID80993305
Created by
admin on Mon Mar 31 20:55:38 GMT 2025 , Edited by admin on Mon Mar 31 20:55:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS |